2024
Care interruptions and mortality among adults in Europe and North America
Trickey A, Zhang L, Rentsch C, Pantazis N, Izquierdo R, Antinori A, Leierer G, Burkholder G, Cavassini M, Palacio-Vieira J, Gill M, Teira R, Stephan C, Obel N, Vehreschild J, Sterling T, Van Der Valk M, Bonnet F, Crane H, Silverberg M, Ingle S, Sterne J. Care interruptions and mortality among adults in Europe and North America. AIDS 2024, 38: 1533-1542. PMID: 38742863, PMCID: PMC11239093, DOI: 10.1097/qad.0000000000003924.Peer-Reviewed Original ResearchCare interruptionsMortality riskCohort studyHazard ratioAnalysis of cohort studiesAntiretroviral therapyCare of peopleRobust to sensitivity analysesMortality hazard ratioCrude mortality rateHazard of mortalityAntiretroviral therapy initiationObservational cohort studyAntiretroviral therapy startUninterrupted careFollow-up groupCareAssociated with adverse outcomesPWHCox regressionAdverse outcomesFollow-up timeMortality rateCompare hazardsComposite outcome
2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology 2022, 4: e490-e506. PMID: 35698725, PMCID: PMC9179144, DOI: 10.1016/s2665-9913(22)00098-4.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesCOVID-19-related deathsSevere COVID-19 outcomesImmune-modifying therapiesCritical care admissionInflammatory diseasesCOVID-19 outcomesImmune-modifying drugsHospital admissionGeneral populationCare admissionHazard ratioStandard systemic therapyStandard systemic treatmentSevere COVID-19Primary care recordsPrimary care dataNon-white ethnic groupsCohort studySystemic therapySystemic treatmentCox regressionPrescription dataCare recordsWhite ethnic groupAssociation between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study
Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, Morton CE, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch CT, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Cockburn J, McDonald HI, Mathur R, Wing K, Forbes H, Eggo RM, Evans SJ, Smeeth L, Goldacre B, Douglas IJ, . Association between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study. British Journal Of General Practice 2022, 72: bjgp.2021.0689. PMID: 35440465, PMCID: PMC9037187, DOI: 10.3399/bjgp.2021.0689.Peer-Reviewed Original ResearchConceptsCOVID-19 outcomesPopulation-based cohort studySevere COVID-19 outcomesSARS-CoV-2Oral anticoagulantsLower riskVASc scoreCohort studyHazard ratioAtrial fibrillationCOVID-19 related outcomesCOVID-19-related deathsPrescribed oral anticoagulantsPrimary care dataBaseline stroke riskOAC useCurrent useStroke riskHospital admissionThrombotic eventsCox regressionOAC usersReduced infection riskGeneral practiceDeath records
2021
Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysisUse of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath
2020
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Schultze A, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Bacon S, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Mathur R, Drysdale H, Wong AYS, McDonald HI, Cockburn J, Forbes H, Parry J, Hester F, Harper S, Smeeth L, Douglas IJ, Dixon WG, Evans SJW, Tomlinson L, Goldacre B. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology 2020, 3: e19-e27. PMID: 33349815, PMCID: PMC7745258, DOI: 10.1016/s2665-9913(20)30378-7.Peer-Reviewed Original ResearchCOVID-19 mortalitySystemic lupus erythematosusPopulation-based cohort studyLupus erythematosusRheumatoid arthritisOpenSAFELY platformCohort studyImmunosuppressive drugsRheumatological diseasesSevere acute respiratory syndrome coronavirus 2National primary care dataAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Effectiveness of hydroxychloroquinePre-exposure usePrimary care dataSyndrome coronavirus 2COVID-19 outbreakCumulative COVID-19 mortalityCOVID-19Medical Research CouncilNegative control outcomesCOVID-19 deathsHydroxychloroquine useCox regression